Literature DB >> 25553175

Bone marrow metastasis of prostatic adenocarcinoma with post-treatment foamy-like changes: A diagnostic pitfall.

Nuri Yigit1, Julia Turbiner Geyer2.   

Abstract

Prostatic acinar adenocarcinoma (PAA) is the most common malignant tumour of the male genital system. Hormonal therapy and radiotherapy are widely-used treatment modalities in advanced stage disease. However, with hormonal therapy, the morphology of the neoplastic cells can be altered with a shift towards benign-appearing cells with inconspicuous nucleoli and abundant cytoplasm. When the tumour spreads to the bone marrow, these neoplastic cells can mimic foamy histiocytes, which may lead to a misdiagnosis. This becomes more challenging if a concurrent bone marrow malignancy is identified. Attention should be paid if foamy cells are detected in bone marrow, particularly if the patient has a history of PAA. To the best of our knowledge, this is the first report of simultaneous bone marrow involvement by metastatic PAA with mimicking foamy histiocytes and lymphoplasmacytic lymphoma.

Entities:  

Year:  2014        PMID: 25553175      PMCID: PMC4277542          DOI: 10.5489/cuaj.2402

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  9 in total

Review 1.  Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol.

Authors:  K N Naresh; I Lampert; R Hasserjian; D Lykidis; K Elderfield; D Horncastle; N Smith; W Murray-Brown; G W Stamp
Journal:  J Clin Pathol       Date:  2006-09       Impact factor: 3.411

2.  Detection of the bcr/abl gene in bone marrow macrophages in CML and alterations during interferon therapy--a fluorescence in situ hybridization study on trephine biopsies.

Authors:  J Thiele; B Schmitz; R Fuchs; H M Kvasnicka; J Lorenzen; R Fischer
Journal:  J Pathol       Date:  1998-11       Impact factor: 7.996

3.  Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy.

Authors:  W P Vaughan; J E Karp; P J Burke
Journal:  J Clin Oncol       Date:  1983-03       Impact factor: 44.544

4.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

5.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

Authors:  G L Wright; B M Grob; C Haley; K Grossman; K Newhall; D Petrylak; J Troyer; A Konchuba; P F Schellhammer; R Moriarty
Journal:  Urology       Date:  1996-08       Impact factor: 2.649

6.  Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.

Authors:  F Civantos; M A Marcial; E R Banks; C K Ho; V O Speights; P A Drew; W M Murphy; M S Soloway
Journal:  Cancer       Date:  1995-04-01       Impact factor: 6.860

7.  Bone marrow metastases: a survey of nonhematologic metastases with immunohistochemical study of metastatic carcinomas.

Authors:  Chandra Krishnan; Tracy I George; Daniel A Arber
Journal:  Appl Immunohistochem Mol Morphol       Date:  2007-03

8.  Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy.

Authors:  Yasuhide Kitagawa; Kiyoshi Koshida; Atsushi Mizokami; Kazuto Komatsu; Shinichi Nakashima; Toshimitsu Misaki; Tetsuo Katsumi; Mikio Namiki
Journal:  Int J Urol       Date:  2003-07       Impact factor: 3.369

9.  Metachronous malignancies in men with previous prostate cancer in Umbria, Italy, 1994-2003.

Authors:  Tiziana Cassetti; Fabrizio Stracci; Liliana Minelli; Massimo Scheibel; Ida Elena Sapia; Francesco La Rosa
Journal:  Tumori       Date:  2008 Jan-Feb
  9 in total
  1 in total

1.  Post-Chemotherapy Foamy Histiocytes in Bone Marrow Aspiration of a Child with Acute Lymphoblastic Leukemia

Authors:  Moeinadin Safavi; Zohreh Nozarian; Farzad Kompani
Journal:  Turk J Haematol       Date:  2021-01-14       Impact factor: 1.831

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.